AB ANALITICA
LIVE

Serial Number

79399168

Owner

AB ANALITICA S.r.l.

Attorney

Robert S. Broder

Filing Date

Mar 21, 2024

Add to watchlist:

No watchlists yet
View on USPTO

AB ANALITICA Trademark

Serial Number: 79399168 • Registration: 8054659

AB ANALITICA is a trademark filed by AB ANALITICA S.r.l. on March 21, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

AB ANALITICA S.r.l. (2 trademarks)

Via Svizzera n° 16

Entity Type: 98

Trademark Details

Filing Date

March 21, 2024

Registration Date

December 9, 2025

Published for Opposition

October 21, 2025

Goods & Services

Gastrointestinal treatment preparations; medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases;  milk sugar for pharmaceutical purposes; vaccines; diagnostic preparations for medical purposes; diagnostic preparations and substances for medical purposes; clinical medical reagents; clinical diagnostic reagents for medical use; diagnostic agents for medical use; diagnostic substances for medical use; diagnostic agents for pharmaceutical use; biological indicators for medical diagnosis; pregnancy testing preparations; in vitro diagnostic preparations for medical use; chemical reagents for in-vitro veterinary purposes for use by veterinary laboratories; chemical reagents for in-vitro medical purposes for use by medical laboratories; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical compounds for treating cancer; male fertility test kits; reagents for medical use; diagnostic reagents for medical use; biological reagents for medical use; chemical reagents for medical use; reagents for use with analyzers for medical purposes; diagnostic chemical reagents for medical use; reagents for use in analysis for medical purposes; chemical test reagents for medical purposes; diagnostic biomarker reagents for medical purposes; reagents for use in diagnostic tests for medical purposes; reagents for microbiological analysis for medical purposes; chemical reagents for medical or veterinary purposes; reagents for use in medical genetic testing; reagents for use in diagnostic tests for veterinary purposes; reagents for analytical purposes for medical purposes; medical diagnostic reagents and assays for testing of body fluids; reagents for use in diagnostic pregnancy tests; reagents for use in analysis for veterinary purposes; culture media for medical use;  reagents for use in veterinary genetic testing; biochemical preparations for medical use; preparations for detecting mutation in prion genes for medical purposes; preparations for detecting genetic predispositions for medical purposes; glucose for medical purposes; glucose dietary supplements; glucose for use as an additive to foods for medical purposes; pharmaceutical preparations for the prevention of disorders of the metabolic system; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating gastrointestinal disorders; antivirals in the nature of DNA synthesis inhibitors; chemical preparations for use in DNA analysis for medical purposes; dietary supplements and dietetic preparations; diagnostic preparations for medical or veterinary purposes.

Pharmaceutical drug development services; research on the subject of pharmaceuticals; scientific research in the field of pharmacy; medical and pharmacological research services; medical research laboratory services; testing of pharmaceuticals; research and development of vaccines and medicines; design and development of medical diagnostic apparatus; scientific research for medical purposes in the area of cancerous diseases; research and development in the field of diagnostic preparations; genetic research; scientific research in the field of genetics and genetic engineering; scientific research relating to genetics; laboratory research in the field of gene expression; DNA screening for scientific research purposes; laboratory research services, namely, DNA testing services to determine paternity; testing for new product development; design and testing for new product development; testing of new product designs for others; new product design; quality control for others; design and testing for new product development; design and testing of new products; scientific research and development; pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; scientific research and development services; research and development of computer software; development and testing of chemical production methods; quality control of manufactured goods; design and development of computer hardware; software design and development; design of instruments; design services relating to data processing tools; design and development of diagnostic apparatus; product research and development; computer design research; development of pharmaceutical preparations and medicines; scientific investigations for medical purposes; biological research, clinical research and medical research; research in the field of pharmacogenetics; laboratory testing of materials; laboratory services for medical research; research and development in the field of microorganisms and cells; research relating to molecular sciences; research and development in the field of biotechnology; bacteriological research; toxicology testing for research purposes; biological research and analysis; physics research; chemical research; scientific research relating to biology; biological research laboratory services; research and development services in the field of immunohistology; provision of medical research services; leasing of scientific laboratory research instruments; computer rental; software development, programming and implementation; data mining; computer software design and updating; preparation of technical reports in the pharmaceutical field; preparation of scientific reports in the pharmaceutical field; technological research in the pharmaceutical field; scientific analysis in the field of molecular biology; biological research.

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 23, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 3, 2026 FICS
FINAL DISPOSITION PROCESSED
Jul 3, 2026 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 9, 2026 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 18, 2025 OPNX
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 9, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 9, 2025 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 3, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 3, 2025 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 21, 2025 NPUB
PUBLISHED FOR OPPOSITION
Oct 21, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 15, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 22, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 22, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 22, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 22, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 22, 2025 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 9, 2025 GNRN
NON-FINAL ACTION E-MAILED
Mar 9, 2025 GNRT
NON-FINAL ACTION WRITTEN
Mar 9, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 5, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 5, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 5, 2025 TROA
REFUSAL PROCESSED BY IB
Nov 2, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 11, 2024 RFCS
REFUSAL PROCESSED BY MPU
Oct 11, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 9, 2024 RFCR
NON-FINAL ACTION WRITTEN
Oct 8, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 28, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 12, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 12, 2024 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 8, 2024 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 4, 2024 REPR